Amino Acid Metabolism Practice Questions

Q: Which of the following enzymes is not involved in the urea cycle?

Glucose-6-phosphatase. ***Glucose-6-phosphatase*** - This enzyme is crucial in **gluconeogenesis** and **glycogenolysis**, catalyzing the final step in the release of glucose from the liver into the bloodstream. It is not part of the **urea cycle**. - Its primary role is to convert **glucose-6-phosphate** to glucose, which is essential for maintaining blood glucose levels. *Ornithine transcarbamylase* - This enzyme is an integral part of the **urea cycle**, catalyzing the reaction of **carbamoyl phosphate** and **ornithine** to form citrulline. - A deficiency in ornithine transcarbamylase leads to **hyperammonemia**, as ammonia cannot be properly converted to urea. *Carbamoyl phosphate synthetase I* - This enzyme is the **rate-limiting step** of the urea cycle, responsible for the synthesis of **carbamoyl phosphate** from ammonia, bicarbonate, and ATP. - It commits ammonia to the urea cycle, making it essential for **detoxification** of nitrogenous waste. *Arginase* - Arginase is the final enzyme in the **urea cycle**, converting **arginine** into **ornithine** and urea. - This reaction releases urea, which is then excreted from the body, and regenerates ornithine to continue the cycle.

Q: In the urea cycle, which enzyme catalyzes the formation of argininosuccinate from citrulline and aspartate?

Argininosuccinate synthetase. ***Argininosuccinate synthetase*** - This enzyme catalyzes the **ATP-dependent condensation** of **citrulline** and **aspartate** to form **argininosuccinate**. - It is a crucial step in the urea cycle, serving the primary purpose of incorporating the second nitrogen atom (from aspartate) into the urea molecule. *Carbamoyl phosphate synthetase I* - This enzyme catalyzes the **first committed step** of the urea cycle, forming **carbamoyl phosphate** from ammonia, carbon dioxide, and ATP. - It is located in the mitochondria and is the **rate-limiting step** of the urea cycle. *Ornithine transcarbamylase* - This enzyme catalyzes the reaction where **carbamoyl phosphate** condenses with **ornithine** to form **citrulline**. - It acts after carbamoyl phosphate synthetase I in the mitochondrial matrix. *Arginase* - This enzyme catalyzes the **final step** of the urea cycle, hydrolyzing **arginine** into **urea** and **ornithine**. - The ornithine is then regenerated and re-enters the cycle.

Q: A patient presents with diarrhea, dermatitis, and dementia. Which amino acid metabolism defect is likely responsible?

Hartnup disease. ***Hartnup disease*** - This condition is caused by a defect in the **tryptophan absorption** from the diet and reabsorption in the kidneys, leading to **tryptophan deficiency**. - Tryptophan is a precursor for **niacin (vitamin B3)**, and its deficiency results in pellagra-like symptoms: **diarrhea, dermatitis, and dementia**. *Phenylketonuria* - This is an inability to metabolize **phenylalanine**, leading to its accumulation and causing **intellectual disability, seizures, and hypopigmentation**. - It does not present with the "3 D's" (diarrhea, dermatitis, dementia). *Homocystinuria* - This disorder involves the metabolism of **methionine**, leading to the accumulation of **homocysteine**, which affects connective tissue, muscles, the central nervous system, and the cardiovascular system. - Clinical features include **ectopia lentis**, developmental delay, and **thrombosis**, not the symptoms described. *Maple syrup urine disease* - This condition involves a defect in the metabolism of **branched-chain amino acids** (leucine, isoleucine, valine), leading to their accumulation. - It causes **poor feeding, vomiting, lethargy, and a characteristic sweet smell** in urine, but not diarrhea, dermatitis, or dementia.

Q: What is the clinical significance of elevated levels of homocysteine?

It is a risk factor for cardiovascular diseases. ***It is a risk factor for cardiovascular diseases*** - Elevated **homocysteine** levels are associated with increased risk of **atherosclerosis**, **coronary artery disease**, **stroke**, and **peripheral vascular disease**. - High levels may promote **endothelial dysfunction**, oxidative stress, and inflammation, contributing to cardiovascular pathology. *It indicates high levels of vitamin B12* - **High homocysteine** levels are typically indicative of **deficiencies in vitamin B12**, folate, or vitamin B6, which are crucial for its metabolism [1]. - Therefore, an inverse relationship exists; deficiency, not high levels, of B12 results in elevated homocysteine [1]. *It is associated with decreased risk of diabetes* - There is no evidence suggesting elevated homocysteine is associated with a decreased risk of **diabetes**. - In fact, some studies show a positive correlation between **hyperhomocysteinemia** and an increased risk of developing **type 2 diabetes**. *It suggests enhanced lipid metabolism* - Elevated **homocysteine** levels are associated with impaired, rather than enhanced, **lipid metabolism** and are often linked with **dyslipidemia**. - Poor lipid metabolism can worsen the **atherogenic effects** of high homocysteine.

Q: A 2-month-old infant presents with vomiting, lethargy, and metabolic acidosis. Blood tests reveal elevated levels of ammonia. What is the most likely diagnosis?

Urea Cycle Disorder. ***Urea Cycle Disorder*** - The combination of **vomiting**, **lethargy**, metabolic acidosis, and **elevated ammonia** in a 2-month-old infant is highly indicative of a urea cycle disorder due to the impaired detoxification of ammonia. - **Ammonia is neurotoxic**, explaining the lethargy, and its accumulation leads to severe metabolic derangements. *Phenylketonuria* - Characterized by the inability to metabolize **phenylalanine**, leading to its accumulation and neurological damage. - While it can cause developmental delay and seizures, it typically does **not present with acute metabolic acidosis** or hyperammonemia in infancy. *Galactosemia* - An inherited disorder of **galactose metabolism** that can cause vomiting, lethargy, and liver dysfunction, but is typically associated with **jaundice**, hepatomegaly, and **reducing substances in urine**, not primarily hyperammonemia and metabolic acidosis as the presenting features. - The primary defect is in the conversion of galactose to glucose, not ammonia detoxification. *Maple Syrup Urine Disease* - A rare metabolic disorder caused by a defect in the metabolism of **branched-chain amino acids** (leucine, isoleucine, valine). - Presents with feeding difficulties, lethargy, and a characteristic **sweet-smelling urine** ("maple syrup" odor), which is not mentioned in this case.

Q: A newborn exhibits severe mental retardation and a musty body odor. What is the likely diagnosis based on these clinical features?

Phenylketonuria. ***Phenylketonuria*** - **Phenylketonuria (PKU)** is an autosomal recessive disorder characterized by the inability to metabolize **phenylalanine**, leading to its accumulation. - Classic symptoms in untreated individuals include **severe intellectual disability**, **seizures**, and a distinct **musty body odor** due to the accumulation of phenylacetic acid. *Alkaptonuria* - This disorder is characterized by the accumulation of **homogentisic acid**, which leads to **dark urine** upon standing and bluish-black pigmentation of cartilage and connective tissues (**ochronosis**). - It does not typically present with severe mental retardation or a musty body odor in infancy. *Maple syrup urine disease* - This metabolic disorder is characterized by the inability to metabolize **branched-chain amino acids** (leucine, isoleucine, and valine), leading to their accumulation. - Key features include neurological damage, feeding difficulties, and a characteristic **sweet, maple syrup-like odor in urine** and earwax, not a musty odor. *Homocystinuria* - This is a disorder of methionine metabolism, leading to the accumulation of **homocysteine** in the blood and urine. - Clinical features include **ectopia lentis** (dislocation of the lens), skeletal abnormalities, thrombotic events, and **developmental delay** or intellectual disability, but not a musty body odor.

Q: What is the effect of a defect in the enzyme phenylalanine hydroxylase on neurotransmitter synthesis?

Decreased dopamine production. ***Decreased dopamine production*** - A defect in **phenylalanine hydroxylase (PAH)** leads to **phenylketonuria (PKU)**, characterized by an accumulation of phenylalanine. - High phenylalanine levels competitively inhibit the enzyme **tyrosine hydroxylase**, which is crucial for the conversion of tyrosine to **L-DOPA**, a precursor to **dopamine** and other catecholamines. - This represents the **most direct enzymatic effect** of PAH deficiency on neurotransmitter synthesis. *Decreased serotonin production* - While serotonin production is indeed decreased in PKU, this occurs through an **indirect mechanism**. - High phenylalanine competitively inhibits the **large neutral amino acid transporter (LAT1)** at the blood-brain barrier, reducing tryptophan entry into the brain. - However, this is a **competitive transport effect**, not a direct enzymatic block like with dopamine synthesis. *Decreased norepinephrine synthesis* - **Norepinephrine** is synthesized from **dopamine** via dopamine β-hydroxylase. - Decreased dopamine production will subsequently lead to decreased norepinephrine synthesis. - However, this is a **downstream consequence** of the primary defect in dopamine synthesis, making it less direct than the dopamine effect itself. *Increased glutamate synthesis* - **Glutamate** synthesis occurs primarily from **alpha-ketoglutarate** in the Krebs cycle or from glutamine via glutaminase. - There is no direct mechanism by which a defect in **phenylalanine hydroxylase** would lead to increased glutamate synthesis. - While chronic high phenylalanine can cause excitotoxicity and neuronal damage, this does not result in increased overall glutamate synthesis.

Q: A patient with a history of recurrent kidney stones is diagnosed with cystinuria. Which amino acid transport defect is most likely?

Cysteine. ***Cysteine*** - Cystinuria is an inherited autosomal recessive disorder characterized by defective transport of **cystine** (the oxidized dimer of cysteine) and the dibasic amino acids (lysine, ornithine, arginine) in the renal proximal tubules and intestinal epithelium. - The transport defect leads to increased urinary excretion of **cystine**, which has poor solubility in acidic urine, resulting in formation of hexagonal **cystine stones** in the kidneys, ureters, and bladder. - The primary defect is in the **rBAT-b0,+AT amino acid transporter system**, which normally reabsorbs cysteine (which oxidizes to cystine in urine) and dibasic amino acids. - This explains the patient's recurrent kidney stones and makes **cysteine transport defect** the correct answer. *Lysine* - While **lysine** is one of the dibasic amino acids whose reabsorption is impaired in cystinuria, it does not precipitate to form stones. - Lysine remains soluble in urine despite increased urinary excretion, so it does not contribute to nephrolithiasis. - The clinical manifestations of cystinuria are due to **cystine stone formation**, not lysine accumulation. *Histidine* - **Histidine** is a basic amino acid, but it is not one of the primary amino acids affected by the transport defect in classic cystinuria. - The main amino acids involved are cystine and the dibasic amino acids: **lysine, ornithine, and arginine** (mnemonic: COLA). - Histidine transport is generally preserved in cystinuria. *Arginine* - **Arginine** is another dibasic amino acid whose tubular reabsorption is defective in cystinuria, along with lysine and ornithine. - However, like lysine, **arginine** remains soluble in urine and does not precipitate to form stones. - The pathology and clinical presentation are driven by **cystine precipitation**, not arginine accumulation.

Q: In the metabolism of amino acids, what is the significance of the enzyme glutamate dehydrogenase?

It converts glutamate to alpha-ketoglutarate. ***It converts glutamate to alpha-ketoglutarate*** - **Glutamate dehydrogenase** catalyzes the **oxidative deamination** of glutamate, producing **alpha-ketoglutarate** and releasing ammonia. - This reaction is crucial for funneling nitrogen from amino acids into the **urea cycle** and carbon skeletons into the **TCA cycle**. *It synthesizes glutamate from ammonia* - While glutamate dehydrogenase can catalyze the reverse reaction (reductive amination) under certain conditions, its primary physiological role in amino acid catabolism is the **degradation of glutamate**, not its synthesis. - The synthesis of glutamate from ammonia can occur via glutamate dehydrogenase or **glutamate synthase (GOGAT)** in various tissues. *It degrades excess amino acids* - Glutamate dehydrogenase primarily acts on **glutamate**, not directly on a wide range of excess amino acids. - It plays a key role in the **final common pathway for nitrogen removal** from many amino acids through glutamate. *It facilitates the uptake of amino acids into cells* - **Glutamate dehydrogenase** is an intracellular enzyme involved in metabolism, not in membrane transport processes. - **Amino acid transporters** are responsible for facilitating the uptake of amino acids into cells.

Q: A patient with maple syrup urine disease has a deficiency in which of the following enzymes?

Branched-chain α-keto acid dehydrogenase. ***Branched-chain α-keto acid dehydrogenase*** - **Maple syrup urine disease (MSUD)** is caused by a deficiency in the **branched-chain α-keto acid dehydrogenase (BCKDH)** complex. - This enzyme is crucial for the catabolism of **branched-chain amino acids (BCAAs)**: leucine, isoleucine, and valine, leading to their toxic accumulation. *Phenylalanine hydroxylase* - A deficiency in **phenylalanine hydroxylase** causes **phenylketonuria (PKU)**, not MSUD. - This enzyme converts phenylalanine to tyrosine; its absence leads to the accumulation of **phenylalanine** and its metabolites. *Homogentisate oxidase* - A deficiency in **homogentisate oxidase** is responsible for **alkaptonuria**. - This enzyme is involved in the breakdown of **tyrosine**, leading to the accumulation of **homogentisic acid**. *Fumarylacetoacetate hydrolase* - A deficiency in **fumarylacetoacetate hydrolase** causes **hereditary tyrosinemia type 1 (HT1)**. - This enzyme is the final step in the degradation of **tyrosine**, and its deficiency leads to the accumulation of toxic metabolites like succinylacetone.

Question 1

Which of the following enzymes is not involved in the urea cycle?

Accepted Answer

Glucose-6-phosphatase

Answer

Ornithine transcarbamylase

Answer

Carbamoyl phosphate synthetase I

Answer

Arginase

Question 2

In the urea cycle, which enzyme catalyzes the formation of argininosuccinate from citrulline and aspartate?

Accepted Answer

Argininosuccinate synthetase

Answer

Carbamoyl phosphate synthetase I

Answer

Ornithine transcarbamylase

Answer

Arginase

Question 3

A patient presents with diarrhea, dermatitis, and dementia. Which amino acid metabolism defect is likely responsible?

Accepted Answer

Hartnup disease

Answer

Phenylketonuria

Answer

Homocystinuria

Answer

Maple syrup urine disease

Question 4

What is the clinical significance of elevated levels of homocysteine?

Accepted Answer

It is a risk factor for cardiovascular diseases

Answer

It indicates high levels of vitamin B12

Answer

It is associated with decreased risk of diabetes

Answer

It suggests enhanced lipid metabolism

Question 5

A 2-month-old infant presents with vomiting, lethargy, and metabolic acidosis. Blood tests reveal elevated levels of ammonia. What is the most likely diagnosis?

Accepted Answer

Urea Cycle Disorder

Answer

Phenylketonuria

Answer

Galactosemia

Answer

Maple Syrup Urine Disease

Question 6

A newborn exhibits severe mental retardation and a musty body odor. What is the likely diagnosis based on these clinical features?

Accepted Answer

Phenylketonuria

Answer

Alkaptonuria

Answer

Maple syrup urine disease

Answer

Homocystinuria

Question 7

What is the effect of a defect in the enzyme phenylalanine hydroxylase on neurotransmitter synthesis?

Accepted Answer

Decreased dopamine production

Answer

Decreased serotonin production

Answer

Decreased norepinephrine synthesis

Answer

Increased glutamate synthesis

Question 8

A patient with a history of recurrent kidney stones is diagnosed with cystinuria. Which amino acid transport defect is most likely?

Accepted Answer

Cysteine

Answer

Lysine

Answer

Histidine

Answer

Arginine

Question 9

In the metabolism of amino acids, what is the significance of the enzyme glutamate dehydrogenase?

Accepted Answer

It converts glutamate to alpha-ketoglutarate

Answer

It synthesizes glutamate from ammonia

Answer

It degrades excess amino acids

Answer

It facilitates the uptake of amino acids into cells

Question 10

A patient with maple syrup urine disease has a deficiency in which of the following enzymes?

Accepted Answer

Branched-chain α-keto acid dehydrogenase

Answer

Phenylalanine hydroxylase

Answer

Homogentisate oxidase

Answer

Fumarylacetoacetate hydrolase

Amino Acid Metabolism — MCQs

Amino Acid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?